Diagnos Laboratorium Financials
| DGNS Stock | IDR 224.00 4.00 1.75% |
Diagnos |
Understanding current and past Diagnos Laboratorium Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Diagnos Laboratorium's financial statements are interrelated, with each one affecting the others. For example, an increase in Diagnos Laboratorium's assets may result in an increase in income on the income statement.
Diagnos Laboratorium Stock Summary
Diagnos Laboratorium competes with Prodia Widyahusada, Medikaloka Hermina, Digital Mediatama, Integra Indocabinet, and Multistrada Arah. PT Diagnos Laboratorium Utama Tbk provides health services using laboratories. The company was founded in 2007 and is headquartered in Jakarta Pusat, Indonesia. Diagnos Laboratorium operates under Diagnostics Research classification in Indonesia and is traded on Jakarta Stock Exchange. It employs 406 people.| Foreign Associate | USA |
| Instrument | Indonesia Stock View All |
| Exchange | Jakarta Exchange |
| ISIN | ID1000158702 |
| Business Address | Gedung Graha Anam |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Benchmark | Dow Jones Industrial |
| Website | diagnos.co.id |
| Phone | 62 21 3193 1833 |
| Currency | IDR - Indonesian Rupiah |
You should never invest in Diagnos Laboratorium without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Diagnos Stock, because this is throwing your money away. Analyzing the key information contained in Diagnos Laboratorium's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Diagnos Laboratorium Key Financial Ratios
Diagnos Laboratorium's financial ratios allow both analysts and investors to convert raw data from Diagnos Laboratorium's financial statements into concise, actionable information that can be used to evaluate the performance of Diagnos Laboratorium over time and compare it to other companies across industries.| Return On Equity | 0.0603 | |||
| Return On Asset | 0.0297 | |||
| Number Of Employees | 568 | |||
| Beta | 0.89 | |||
| Z Score | 17.8 |
Diagnos Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Diagnos Laboratorium's current stock value. Our valuation model uses many indicators to compare Diagnos Laboratorium value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Diagnos Laboratorium competition to find correlations between indicators driving Diagnos Laboratorium's intrinsic value. More Info.Diagnos Laboratorium Utama is one of the top stocks in return on equity category among its peers. It also is one of the top stocks in return on asset category among its peers reporting about 0.49 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Diagnos Laboratorium Utama is roughly 2.03 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Diagnos Laboratorium's earnings, one of the primary drivers of an investment's value.Diagnos Laboratorium Systematic Risk
Diagnos Laboratorium's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Diagnos Laboratorium volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was four with a total number of output elements of fifty-seven. The Beta measures systematic risk based on how returns on Diagnos Laboratorium correlated with the market. If Beta is less than 0 Diagnos Laboratorium generally moves in the opposite direction as compared to the market. If Diagnos Laboratorium Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Diagnos Laboratorium is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Diagnos Laboratorium is generally in the same direction as the market. If Beta > 1 Diagnos Laboratorium moves generally in the same direction as, but more than the movement of the benchmark.
Diagnos Laboratorium November 27, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Diagnos Laboratorium help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Diagnos Laboratorium Utama. We use our internally-developed statistical techniques to arrive at the intrinsic value of Diagnos Laboratorium Utama based on widely used predictive technical indicators. In general, we focus on analyzing Diagnos Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Diagnos Laboratorium's daily price indicators and compare them against related drivers.
| Downside Deviation | 3.99 | |||
| Information Ratio | (0.02) | |||
| Maximum Drawdown | 37.5 | |||
| Value At Risk | (5.45) | |||
| Potential Upside | 6.84 |
Other Information on Investing in Diagnos Stock
Diagnos Laboratorium financial ratios help investors to determine whether Diagnos Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Diagnos with respect to the benefits of owning Diagnos Laboratorium security.